UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050211
Receipt number R000056855
Scientific Title THE CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN AMONG PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN JAPAN
Date of disclosure of the study information 2023/02/02
Last modified on 2023/10/21 16:06:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

THE CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN AMONG PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN JAPAN

Acronym

THE CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN AMONG PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN JAPAN

Scientific Title

THE CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN AMONG PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN JAPAN

Scientific Title:Acronym

THE CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN AMONG PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN JAPAN

Region

Japan


Condition

Condition

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

-To describe the clinical, humanistic, and economic burden of PNH on patients currently being treated with C5 inhibitors (either eculizumab or ravulizumab) in Japan
-To analyze the clinical, humanistic, and economic burden of PNH in patients currently being treated with C5 inhibitors by subgroup

Basic objectives2

Others

Basic objectives -Others

Web-based questionnaire survey and paper-based self-completion questionnaire survey on disease burden

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Self-reported hematological and clinical measures (such as diagnosis of ongoing anemia, levels of hemoglobin, history of red blood cell transfusions, history of thrombotic events, and history of renal function impairment)
Quality of life assessed using PRO scales (EQ-5D-5L and EORTC)
Fatigue and depression state assessed using PRO scales (FACIT-Fatigue and PHQ-8)
Impact on work productivity assessed using a PRO scale (WPAI) and impact of C5 inhibitor infusions and blood transfusions assessed using a Likert scale
Self-reported health resource utilization (Number of times in ER and hospitalized)

Key secondary outcomes

Calculation of summary statistics and number and percentage of respondents for the primary endpoints by subgroup described below
-Subgroup
Patients with reported hemoglobin levels of <12 (120) vs >_12 (120) g/dL (g/L) and <10.5 (105) vs >_10.5 (105) g/dL (g/L)
Patients with vs. without a history of transfusion in the past 6 months
Patients with vs. without a history of thrombotic events
Patients classification as separately specified in the Statistical Analysis Plan (SAP)


Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

-18 years old or older
-Self-reported diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH)
-Self-reported that currently being treated with eculizumab or ravulizumab
-Agree to informed consent for the study

Key exclusion criteria

-Correspond to an inappropriate answer

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Tomoyuki
Middle name -
Last name Kusaka

Organization

Social Survey Research Information co., Ltd(SSRI)

Division name

Healthcare BI/MA Service Division

Zip code

162-0067

Address

10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067 JAPAN

TEL

03-6709-9710

Email

hor@ssri.com


Public contact

Name of contact person

1st name Moemi
Middle name
Last name Miura

Organization

Social Survey Research Information co., Ltd(SSRI)

Division name

Health outcomes research, HBI/MA Service Division

Zip code

162-0067

Address

10-5 Tomihisacho, Shinjuku-ku, Tokyo 162-0067 JAPAN

TEL

03-6709-9710

Homepage URL


Email

hor@ssri.com


Sponsor or person

Institute

Swedish Orphan Biovitrum Japan

Institute

Department

Personal name



Funding Source

Organization

Swedish Orphan Biovitrum Japan

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kitamachi clinic

Address

1-1-3 Kichijoji-Kitamachi, Musashino-city, Tokyo

Tel

03-6779-8166

Email

chi-pr-ec-kitamachi@cmicgroup.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 02 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

68

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 09 Month 13 Day

Date of IRB

2022 Year 09 Month 21 Day

Anticipated trial start date

2022 Year 09 Month 30 Day

Last follow-up date

2022 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

N/A


Management information

Registered date

2023 Year 02 Month 01 Day

Last modified on

2023 Year 10 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056855


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name